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ABSTRACT
Objectives: Health insurers, physicians, and patients worldwide need
information on the comparative effectiveness and safety of prescription
drugs in routine care. Nonrandomized studies of treatment effects using
secondary databases may supplement the evidence based from randomized
clinical trials and prospective observational studies. Recognizing the chal-
lenges to conducting valid retrospective epidemiologic and health services
research studies, a Task Force was formed to develop a guidance document
on state of the art approaches to frame research questions and report
ﬁndings for these studies.
Methods: The Task Force was commissioned and a Chair was selected
by the International Society for Pharmacoeconomics and Outcomes
Research Board of Directors in October 2007. This Report, the ﬁrst of
three reported in this issue of the journal, addressed issues of framing
the research question and reporting and interpreting ﬁndings.
Results: The Task Force Report proposes four primary characteristics—
relevance, speciﬁcity, novelty, and feasibility while deﬁning the research
question. Recommendations included: the practice of a priori speciﬁcation
of the research question; transparency of prespeciﬁed analytical plans,
provision of justiﬁcations for any subsequent changes in analytical plan,
and reporting the results of prespeciﬁed plans as well as results from
signiﬁcant modiﬁcations, structured abstracts to report ﬁndings with sci-
entiﬁc neutrality; and reasoned interpretations of ﬁndings to help inform
policy decisions.
Conclusions: Comparative effectiveness research in the form of nonran-
domized studies using secondary databases can be designed with rigorous
elements and conducted with sophisticated statistical methods to improve
causal inference of treatment effects. Standardized reporting and careful
interpretation of results can aid policy and decision-making.
Keywords: comparative effectiveness, health policy, nonrandomized
studies, secondary databases.
Background to theTask Force
In September 2007, the International Society for Pharmacoeco-
nomics and Outcomes Research (ISPOR) Health Science Policy
Council recommended that the issue of establishing a Task Force
to recommend Good Research Practices for Designing and Ana-
lyzing Retrospective Databases be considered by the ISPOR
Board of Directors. The Council’s recommendations concerning
this new Task Force were to keep an overarching view toward the
need to ensure internal validity and improve causal inference
from observational studies, review prior work from past and
ongoing ISPOR task forces and other initiatives to establish
baseline standards from which to set an agenda for work. The
ISPOR Board of Directors approved the creation of the Task
Force in October 2007. Task Force leadership and reviewer
groups were ﬁnalized by December 2007 and the ﬁrst teleconfer-
ence took place in January 2008.
Task Force members were experienced in medicine, epidemi-
ology, biostatistics, public health, health economics, and phar-
macy sciences, and were drawn from industry, academia, and as
advisors to governments. The members came from the UK,
Germany, Austria, Canada, and the United States.
Beginning in January 2008, the Task Force conducted
monthly teleconferences to develop core assumptions and an
outline before preparing a draft report. A face-to-face meeting
took place in October 2008 to develop the draft, and three
forums took place at the ISPOR meetings to develop consensus
for the ﬁnal draft reports. The draft reports were posted on the
ISPOR website in May 2009 and the task forces’ reviewer group
and ISPOR general membership were invited to submit their
comments for a 2-week reviewer period. In total, 38 responses
were received. All comments received were posted to the ISPOR
website and presented for discussion at the Task Force forum
during the ISPOR 12th Annual International Meeting in May
2009. Comments and feedback from the forum and reviewer and
membership responses were considered and acknowledged in the
ﬁnal reports. Once consensus was reached, the manuscript was
submitted to Value in Health.
Introduction
Health insurers, physicians, and patients worldwide need infor-
mation on the comparative effectiveness and safety of prescription
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drugs in routine care. Although randomized clinical trials (RCTs)
are the gold standard to determine a drug’s efﬁcacy against
placebo, it is well recognized that results of such studies may not
accurately reﬂect effectiveness of therapies delivered in typical
practice [1–3]. In addition, clinical decisions usually involve
choices among therapies yet sponsors of drug trials have limited
motivation to test new drugs against existing therapies [4]. Rou-
tinely collected and electronically stored information on health-
care utilization in everyday clinical practice has proliferated over
the past several decades. Large computerized databases with
millions of observations of the use of drugs, biologics, devices, and
procedures along with health outcomes may be useful in assessing
which treatments are most effective and safe in routine care
without long delays and the prohibitive costs of most RCTs.
There is controversy, however, on how to best design and
analyze nonrandomized studies on comparative treatment effects
using secondary databases, including claims databases, patient
registries, electronic medical record databases, and other rou-
tinely collected health-care data. Challenges of conducting epi-
demiologic and health services research studies from secondary
data sources include concerns about the adequacy of study
design, the relevance of the population and timeframe available
for study, approaches to minimize confounding in the absence of
randomization, and the speciﬁcity of clinical outcome assess-
ment. Such threats to validity limit the usefulness of these studies
and adoption of ﬁndings into policy and practice. With proper
research design and application of an array of traditional and
newer analytic approaches, such concerns can be addressed to
improve our understanding of treatment effects. (See Parts II and
III of this Task Force Report, also in this issue [5,6].) This report
will suggest that to optimize the validity of ﬁndings from obser-
vational studies designed to inform health-care policy decisions,
researchers employ a priori hypotheses in written protocol and
data analysis plans before study implementation, that they
follow reporting standards that make transparent to readers if,
why, and how their analytic plans evolved, as well as provide a
justiﬁcation of the suitability of the database to test their
hypotheses.
Although we recognize that exploratory analyses and data
mining of large datasets are often used to generate hypotheses
regarding the effectiveness and comparative effectiveness of treat-
ments, stricter criteria for the design and execution of studies as
well as transparency in their reporting are required to justify the
conclusion that such ﬁndings are robust enough to warrant
changes in clinical practice or to inﬂuence policy decisions.
Thus, the objective of this report is to lay out good research
practices for comparative therapeutic effectiveness studies using
secondary databases. We present the report in three sections:
Deﬁning, Reporting and Interpreting Nonrandomized Studies;
Design Issues; and Analytical Issues. By describing best practice,
this report will serve to improve future research, assist in evalu-
ating the validity of existing studies, and suggest how these
studies should be interpreted for decision-making; it may also be
of use to journal editors who are responsible for the peer-review
process for publication. We do not seek to be complete in our
discussion of analytic options, nor will we fully explain all
methods, but rather focus on the issues surrounding the most
relevant designs and analytic techniques for secondary databases.
It is important to be explicit about the deﬁnition of compara-
tive effectiveness as it is applied by the authors of this report.
With respect to the term comparative, this report will focus on
the majority of circumstances when comparison can be made
between two or more active treatments rather than comparisons
made between an active treatment and “no treatment.” With
respect to the term effectiveness, this report will focus on the
beneﬁts of therapies evaluated rather than harms (as extensively
examined in the ﬁeld of pharmacoepidemiology) or costs (as
extensively examined in pharmacoeconomics and health services
research).
The assessment of the comparative beneﬁts of various treat-
ment options through the analysis of secondary databases is
controversial. Nevertheless, policymakers, payers, and provid-
ers are increasingly turning to the analysis of large secondary
databases to answer a variety of questions. For example, when
there are no head-to-head RCT or prospective observational
study data available, these data sets are used to examine
whether and to what magnitude there are differences in beneﬁt
associated with various treatments including drugs in the same
or different drug classes. Even if there are published head-to-
head clinical trials, there may be a reason to suspect that there
may be clinically or policy important differences in treatment
effectiveness in real-world usage in comparison with the out-
comes observed in RCTs—perhaps driven by differences in
target population, adherence/compliance, or other important
factors. Additionally, RCTs are frequently designed to examine
intermediate or surrogate measures as outcomes; thus, there
may be the desire to examine the magnitude of beneﬁt when
assessed on true outcome measures over longer observation
durations (e.g., mortality, disability). Finally, when decision-
makers want comparative effectiveness data to inform trade-
offs driven by different proﬁles of beneﬁts, harms and costs
among treatment options, secondary databases provide a highly
valuable source of information.
Deﬁning the Question
As we have moved from the early 20th century practice of
medicine—a cottage industry based more on anecdotal experi-
ence and characterized by enormous practice variation—to a
21st century practice that is based upon treatment guidelines and
accountability for quality—a more systematic approach in which
inappropriate practice variation will be discouraged—the inter-
relationship between health-care policy decision-makers and
those generating the evidence to support their decisions has
become more complicated.
Fueling this evolving relationship is the continued rise in
health-care costs at a rate faster than the overall economy. Thus,
governments and payers are making health policy decisions
regarding access and reimbursement of new health-care tech-
nologies that have not always delineated separate answers to the
three cardinal questions of evidence-based technology evaluation
(as set forth by Archie Cochrane): “Can it work? Will it work? Is
it worth it?” [7]. Answering the latter question comprises judg-
ments about both comparative effectiveness (What are the
advantages—from the perspective of the patient, the provider,
and the payer—that a new technology provides over the available
standard of care?) and contextual value considerations (Can we
afford it? Do we get a good “bang for the buck” relative to
alternatives? How does this square with precedent and our col-
lective preferences in allotting scarce resources to health care?).
To adequately answer these questions, the development of
evidence is ideally an iterative process between decision-makers,
those who generate evidence and those who evaluate and sum-
marize the body of evidence relevant to particular health policy
questions [8]. Considering these questions individually—
especially the value question—is critical to a transparent and fair
appraisal process and can be enhanced by appropriate structur-
ing of the process [9].
Questions regarding comparative effectiveness are often
restructured into operational terms such as “How does this drug
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compare to other similar drugs on the formulary in terms of
clinical outcomes?” “What role should a new drug play in the
treatment of a particular condition and how will this be
described in a treatment guideline?” and questions of value are
often worded in terms such as “should we grant reimbursement
for a new drug and at what contract terms or price?”
Because the majority (if not all) of health policy decisions are
made with imperfect information to inform these questions—
due to either imperfect evidence or the absence of the desired
evidence—the decision-making process is confounded further.
When is the evidence “good enough” to make a recommenda-
tion? The alternative—waiting for perfect evidence—is usually
not acceptable, because we never have perfect evidence and we
are incapable (either due to cost or feasibility) to perform “gold
standard” RCTs to answer the myriad questions posed for a
forever-growing armamentarium of health-care technologies.
Hence, we must update the traditional evidence hierarchy [10]
and look to ways to optimize the use of observational data that
will increasingly be automated into health-care delivery.
Currently, there is reluctance by many health policy decision-
makers to use observational data—especially data from retro-
spective analysis of large data sets—to inform their deliberations.
Many decision-makers are uncertain about the reliability and
robustness of results derived from observational studies, prima-
rily because of concerns about confounding and selection bias.
This distrust is derived, at least in part, from the lack of generally
accepted good research practices and lack of standardized report-
ing; it is also due to discordance of the results in examination of
clinical effectiveness between some observational studies and
randomized controlled clinical trials. Understanding the source
of these discordances, in turn, also relies upon a rigorous
approach to the design and analysis of observational studies.
Thus, we believe, that creation and adoption of good observa-
tional research practices will augment their use and credibility.
Prospective Speciﬁcation of Research and
Protocol Development
Arguably, the most important and challenging part of research is
to clearly and precisely articulate the objective of a study in the
form of a focused research question [11,12] before the design
and execution of a study (i.e., a priori). One strength of clinical
trials is the requirement for a study protocol which speciﬁes
inclusion criteria for subjects, primary and secondary outcomes,
and analytic approach. Although there are differing views in
medical science regarding a priori speciﬁcation of a research
hypothesis when conducting observational research [13], prior
speciﬁcation minimizes the risk of “cherry-picking” interesting
ﬁndings and a related issue of observing spurious ﬁndings
because of multiple hypothesis testing [14]. For these reasons,
we recommend the practice of a priori speciﬁcation of the
research question and study design in a formal study protocol
and data-analysis plan is strongly advised to assure end-users
that the results were not the product of data-mining. (Note: this
is not an indictment of data-mining per se; rather that data-
mining is more appropriate for hypothesis generation, rather
than hypothesis testing).
As part of the protocol, the rationale for the observational
study should be explicitly stated. For example, there are no direct
comparative data on the effectiveness of various treatment
options or that available data have only examined the short-term
consequences of treatment and decision-makers were seeking
information on long-term outcomes. When deﬁning the research
question, four primary characteristics are proposed:
Relevance and Rationale
The research questions and hypotheses should be highly topical
and meaningful from a clinical, policy, or research methodology
perspective not only at time of study conception but, perhaps
more importantly, at the anticipated time of submission for pub-
lication or presentation to the relevant audience.
Speciﬁcity
The research question should be concise yet unambiguous,
should relate to the stated research objectives where relevant,
should state the intervention and outcome of interest where
relevant, should identify the patient population, and should focus
on one primary end point. Existing data sources must be
adequate to provide valid identiﬁcation of the appropriate
patients, interventions, and outcomes. The protocol methods
section should discuss the strengths and weaknesses of a second-
ary database with respect to its suitability in answering the
primary research questions.
Novelty
Proposals should clearly identify what a new study can add to
existing knowledge. At one extreme, there may be an absence of
literature that directly relates to the proposed study question
thereby making the proposed research question novel. Alterna-
tively, the proposed study design for the given research question
may improve on previous studies. Previous ﬁndings may have
been inconclusive, conﬂicting or questioned because of study
limitations. Finally, even when some research exists (including
clinical trials), there may be a need to validate ﬁndings. As the
number of well-designed studies addressing a speciﬁc question
whose ﬁndings are consistent with each other increases, the value
of an additional study addressing this question diminishes.
Feasibility
Investigators should recognize that conducting a rigorous obser-
vational study can be as challenging as conducting trials and
should ensure that studies are feasible with respect to power of
the study to answer a question, time and resources required, and
ability to link necessary data sources. There should also be
adequate numbers of patients and events to yield sufﬁcient power
for the primary analysis. Timing can be important because some
areas change so rapidly that the answers may no longer be
relevant if it takes several years to collect and analyze data.
Finally, even where data already exist, there can be substantial
hurdles to linking data from different systems to conduct the
intended analysis.
In formulating the research question with the above-
mentioned characteristics, two suggestions may be helpful: 1)
“begin at the end” [11]; and 2) know the limitations of the
available data. Envisioning the one key table or ﬁgure required to
answer the research question is extremely helpful in focusing the
research question and understanding what can feasibly be
extracted from the available data. Also, a sound understanding
of data limitations will also help to understand which research
questions should or should not be studied with the available data
sources.
Once the research question has been deﬁned, a sound study
protocol should be developed with this study question in mind
[12]. Key components of a study protocol include study back-
ground and rationale, research question/objective, study design,
study population, data sources and storage where relevant, study
timeframe, speciﬁc study deﬁnitions, one prespeciﬁed primary
end point, secondary end points, statistical analysis (including
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sample size and power where relevant), informed consent process
where relevant, and mock output tables and/or ﬁgures [12]. A
written detailed data analysis plan (DAP) should also accompany
the protocol; a good DAP will include deﬁnitions of outcomes,
measures of treatments, and identify all covariates. The DAP
should provide general speciﬁcation of any modeling that is
contemplated. We recognize that analytic plans often require
adjustment once researchers begin to analyze secondary datasets.
We recommend that researchers be transparent about their ex
ante analytic plans, provide justiﬁcation for subsequent changes
in analytic models, and report out the results of their ex ante
analytic plan as well as the results from its modiﬁcations. In
addition, researchers may wish to establish explicit limits on the
evolution of the analytic plan—beyond which any results should
be considered hypothesis-generating—and not appropriate for
making clinical practice or policy recommendations. For
example, one might consider establishing the boundary when a
hypothesis-testing study changes into a hypothesis-generating
study. Following extraction of the analytic dataset and comple-
tion of prespeciﬁed primary analyses, researchers frequently dis-
cover “bugs” in their analyses—perhaps because of coding
problems in the data or because of the algorithms applied to
deﬁne exposure; appropriate correction of these “bugs” is well
accepted. Nevertheless, if important ﬂaws become evident in the
analytic approach such that different analytic approaches must
be applied, this should signal that the study should be considered
hypothesis-generating and not hypothesis-testing.
Recommendations
• A priori speciﬁcation of the research question and study
design in a formal study protocol and data-analysis plan is
strongly advised.
• Be transparent about ex ante analytic plans, provide justi-
ﬁcation for subsequent changes in analytic models, and
report out the results of their ex ante analytic plan as well as
the results from its modiﬁcations.
Selection of Study Design Appropriate to the
Study Question
Although numerous epidemiologic and econometric study
designs exist [15–21], the choice of study design is almost
always determined by both the research question and feasibility
constraints [22,23]. It is crucial to be absolutely uncompro-
mising about design aspects of a study that might hamper
its validity [24]. A detailed review of typical study designs used
in clinical research is provided elsewhere [15–21]. Several
key study designs used in observational research are outlined in
the subsequent sections. Guidelines have recently been pro-
posed on the reporting of observational studies, speciﬁcally as it
relates to cross-sectional, cohort, and case-control studies
[22,23].
Cross-Sectional Designs
The cross-sectional study examines a “snapshot” of data and
typically either describes the data available in that snapshot or
attempts to make correlations between variables available in the
dataset. Although this study design can provide some valuable
information, it is typically limited by its inability to characterize
temporality—it is often uncertain whether the exposure preceded
the outcome of interest or vice versa. In research questions where
temporality of exposure and outcome are important, alternative
designs should be selected.
Cohort Designs
In a cohort study, groups of patients (i.e., cohorts) exposed to
drug therapies are followed over time to compare rates of the
outcomes of interest between the study cohorts. Temporal rela-
tionships between exposure and outcome can be well character-
ized in a cohort study and both relative and absolute risks can be
reported directly with the use of this design. Consequently, this
design may be of particular interest for research questions requir-
ing absolute risk estimates and where the temporal nature of
associations is important to characterize.
Case-Control Designs
Case-control designs involve the identiﬁcation of individuals who
experience an outcome of interest (i.e., the cases) and those who
do not (i.e., controls). Exposure to an intervention of interest in
a period before the designation of case or control status is then
compared between cases and controls. This design has histori-
cally been used when the outcome of interest is rare, maximizing
the capture of such precious outcomes. Analysis of case-control
designs typically provide estimates of relative risk but do not
directly provide absolute risk estimates.
Case-Crossover Designs
A primary challenge of cohort and case-control studies is the
selection of comparable comparison groups. In case-crossover
studies, individuals serve as their own controls. Only those
individuals who experience the outcome of interest (i.e., cases)
and were exposed to a treatment of interest within a certain
time before the outcome date are included. Exposure to the
treatment of interest in the period immediately before the
outcome is compared with the exposure prevalence in a period
more distant to the date of the event of interest in the same
individual. Exposure prevalences are then compared between
more recent and distant exposure windows to arrive at a risk
ratio. Case-crossover designs are ideally suited for transient
exposures that result in acute events but require sufﬁcient
numbers of patients who have both an event and are exposed
to the drug of interest in either the nearby or more distant
exposure windows. This design may be particularly attractive
for research questions involving the comparison of groups that
are extremely different in their clinical proﬁles (i.e., where
major selection bias may exist) and involve transient exposures
and immediate outcomes.
Case-Time-Control Designs
A limitation of case-crossover designs is temporal confounding
where the prevalence of treatment exposure is higher in the
exposure window closer to the event date relative to the exposure
window more distant to the event date simply because of natu-
rally increasing treatment uptake over time rather than a truly
casual relationship. To circumvent this issue, a control group of
individuals who do not experience the event of interest is created
and analyzed in a manner similar to the cases to estimate the
“natural” increase in treatment exposure prevalence over
time—the exposure prevalence in the exposure window closer to
the event date is compared with the exposure prevalence in the
exposure window in a more distant period to arrive at a risk ratio
amongst controls. The “case” risk ratio is then divided by the
“control” risk ratio to arrive at an overall risk ratio. This design
also requires sufﬁcient numbers of patients who have both an
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event and exposure to the treatment of interest in either of the
predeﬁned exposure windows and issues of selection bias in
comparing case to controls may still be problematic [24].
Interrupted Time Series Designs
Interrupted time series analysis typically involve cross-sections
of data over time both before and following an event of interest.
Actual trends in exposures or outcomes following an event of
interest are then compared with expected trends based on pat-
terns of historical data before the event of interest. For example,
in assessing the impact of a drug policy on drug utilization,
historical trends would be used to establish an expected drug
utilization rate in the absence of the policy change [25]. This
expected drug utilization rate would then be compared with
observed rates occurring following the implementation of the
drug policy using advanced statistical approaches. The beneﬁt
of conducting a time series analysis is the minimization of prob-
lematic selection bias. Challenges, however, include issues
related to temporal confounding (i.e., other events that may
have occurred simultaneously at the time of intervention) and
the typical need for relatively large effect sizes. This design may
be particularly relevant for research questions aimed at assess-
ing the impact of events on drug utilization and immediate
outcomes.
Although the above-mentioned descriptions serve a basic
overview of selected study designs in pharmacoepidemiology,
health services and outcomes research, study designs are not
necessarily mutually exclusive. For example, the case-crossover
design is inherent in the case-time-control design, a nested case-
control study may involve a formal cohort study as part of its
case ascertainment [26], and previous research has embedded
cohorts of patients in time series analysis [27].
Explicit in the research question are the exposure and/or
outcome of interest. The nature of the association between the
exposure and outcome is often implied in the research question.
For example, if the research question suggests the measurement
of the incidence of an event, a cohort study design may be
preferred over a case-control study design.
Although the research question establishes the key param-
eters of the association being assessed, feasibility constraints such
as small numbers of available patients and outcomes in the
dataset, data quality, level of funding, and skill level of the
researcher team may signiﬁcantly inﬂuence the study design to be
used in the analysis. For example, in measuring the association
between an exposure and outcome, if the outcome stated in the
research question is extremely rare and a modest budget is avail-
able for prospective data collection, a case-control study may be
preferred over a cohort study.
The Study Question Dictates the Choice of
Data Source
The data source must be able to adequately answer the study
question using the selected research design. Several characteris-
tics of the data source must be taken into consideration includ-
ing the breadth and depth of the data in the database, the
quality of the database, the patient population that contributes
data to the database, and duration of information contained in
the databases. For example, if the study question includes a
highly speciﬁc, well-deﬁned outcome, this outcome must be
captured and well coded in the database being used in the
research.
Two primary types of databases for observational research
exist: medical records databases and administrative databases
[28]. Data in the former are recorded as part of the process of
clinical outpatient care while data in the latter are recorded as
a by-product of ﬁnancial transactions. Consequently, although
administrative databases typically contain more general infor-
mation on very large numbers of patients, medical records
databases typically contain much more detailed clinical infor-
mation on its patients (e.g., smoking status, lab results, and
body mass index) that are often lacking in administrative data-
bases. Medical records data may provide more extensive data
for comorbidity adjustment for research studies that may be
particularly susceptible to selection bias whereas administrative
claims data, if considerably larger in numbers of patients cap-
tured, may be better suited for research questions that involve
rare outcomes.
Electronic medical records (EMR) are emerging as a prom-
ising source of data for clinical research but come with their
own sets of challenges [29], including the development and har-
monization of data standards. Although these EMR-based
datasets can provide a rich base of clinical information that is
often not afforded by administrative databases, challenges
typical of observational research such as selection bias will still
persist.
Merging clinical and administrative datasets also provides the
opportunity to leverage the strengths of each type of data. For
example, rich clinical information for deﬁned sets of patients can
be merged into administrative data to limit the need for prospec-
tive follow-up of outcomes that are routinely collected in admin-
istrative datasets [30]. Although the practice of merging such
datasets has been increasing, the process of merging, privacy
issues, and data quality and transferability must all be considered
as part of the process.
Ultimately, the selected data source will need to have the
required breadth and/or depth, duration, and quality of informa-
tion dictated by the research question to provide ﬁndings mean-
ingful to society.
Reporting
Structured Abstract
Reporting of results is a critical step in the conduct of scientiﬁc
studies. It permits end users to make independent assessment of
the strength and limitations of a study as well as to judge the
robustness of the ﬁndings. In turn, this informs their assessment
about the relevance and weight that study ﬁndings should be
given in subsequent decision-making. This is particularly true
for observational studies. Reporting of observational studies
should allow users to understand clearly the primary question,
reasons for choosing the particular data, the quality of the data
sources, the processes to reduce bias, and the potential for
results to be explained by factors other than a causal effect.
Interpretation of the results should be placed in the context of
other studies, especially randomized studies, and differences
explained.
To this end, a standardized approach to reporting of obser-
vational studies should be adopted, similar to the CONSORT
(Consolidated Standards of Reporting Trials) recommendations
[31] which has been modiﬁed by STROBE (Strengthening the
reporting of observational studies in epidemiology) statement
[23]. The CONSORT and STROBE recommendations could be
adapted as follows:
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SECTION ANDTOPIC ITEM # DESCRIPTOR
Study Design 1 Description of Study
Design
Introduction
• Background
2 Scientiﬁc background
and explanation of
rationale including
discussion of the
suitability of the
database employed
Methods
• Deﬁning the question
• Objectives
• Selection of study design
• Selection of data source
• Deﬁnition of treatment
cohorts
3 Clearly deﬁned goals
of the study with
description of speciﬁc
sub-questions.
Description of study
design and why it was
chosen; Description
of strengths and
weaknesses of data
source and how study
groups were identiﬁed,
including description
of critical variables:
diagnostic criteria,
exposures, and potential
confounders
• Measurement of treatment
effects
• Classiﬁcation bias
4 Discuss how treatment
effects were measured
and how classiﬁcation
bias was addressed.
• Measurement of outcomes
• Classiﬁcation bias
5 Discuss how outcomes
were measured and how
classiﬁcation bias was
addressed.
• Confounding
• By indication
• Measured vs. unmeasured
• Time dependent
• Analytic plan to address
confounding
6 Discuss the potential for
confounding, both
measured and
unmeasured, and how
this was assessed and
addressed
Discussion
• Internal validity 7 Interpretation of results,
taking into account
confounding and
imprecision of results.
• Generalizability 8 Generalizability (external
validity) of the study
ﬁndings.
• Overall evidence 9 General interpretation
of the results in the
context of current
evidence.
When reporting results, the objective is to provide a complete and
transparent record of the conduct of the study. Although there are
accepted criteria to assess the quality of randomized controlled
clinical trials, there are no widely accepted criteria for compara-
tive effectiveness studies on secondary databases. For these
reasons, we believe it is an imperative for researchers to provide a
narrative description within the methods section of a manuscript
of whether and to what extent the prespeciﬁed analytic plan
requiredmodiﬁcation.What did you originally intend to do? If the
analytic plan evolved over time—explain what you found that led
to the modiﬁcation of analyses or models. Report—at least in
summary terms—the results of the prespeciﬁed analytic plan as
well as the ultimate study results. If you had tomake compromises
in the goals of the study, what did you do and why? To the extent
possible, provide an estimate of the expected magnitude of poten-
tial confounding before study execution, or estimate the level of
confounding that would have driven your result back toward the
null hypothesis. We acknowledge that journal editors may not
allow space for this level detailed reporting; nonetheless, we
believe that this will enhance transparency of the research process
and could be included in an appendix.
Interpretation of Results
To interpret the results of observational studies, they must be put
into the larger evidentiary context. When results of an observa-
tional study conﬂict with a well-conducted RCT, possible reasons
for the discrepant ﬁndings should be systematically examined.
These may include:
• Signiﬁcant confounding present, whether or not it can be
identiﬁed. These may include differences in adherence, con-
founding by indication, the impact of out-of-pocket costs,
etc.
• Data quality is poor—biased to null.
• Different question: A different population was studied that
exhibited a different response to therapy.
• Different question: Differential effects on outcomes used in
observational studies and those used in the RCT (effective-
ness vs. efﬁcacy).
If there is no RCT to compare to, then should the results run
counter to current understanding of biology and disease pro-
cesses, they should not be considered as deﬁnitive but warranting
further investigation. Indeed, in general, observational studies
can be used to generate hypotheses worthy of additional study.
As discussed elsewhere in this report, different observational
study designs are better suited to hypothesis generation, such as
cross-sectional studies. In contrast, a good case-control study
may be ideal and informative of causal inferences under some
circumstances (e.g., food borne outbreaks of disease with large
relative risks). Well-conducted time-series studies can provide
quite compelling data to support relative effectiveness in some
circumstances (e.g., cervical cancer screening) and cohort studies
are often good for assessing risks—but are frequently poor at
assessing the effectiveness of interventions.
Second, reproducibility is a hallmark of robust evidence.
Ideally, observational studies using the same analytic approach
should result in substantially similar ﬁndings when applied to
similar populations or different databases. Of course deﬁning
similar can be difﬁcult. Simply demonstrating equivalence in the
distribution of age, gender, ethnicity, or disease prevalence may
not be enough. Differences in outcomes may be explained by
variation in social and economic factors. Thus, the ﬁnding of
reproducibility should enhance conﬁdence in using the outcomes
to inform decision-making; nevertheless, the absence should not
rule out their use in assessing the body of relevant evidence.
Third, one can have greater conﬁdence in the ﬁndings of an
observational study, if an analysis of its cohort that is restricted
to a subpopulation that is comparable with that of a published
RCT provides similar results. Studies that examine an inception
cohort of new users reduce the biases introduced by focusing
on existing users, because nonresponders and those suffering
adverse effects of therapy won’t be represented. This really is
quite helpful because RCTs have higher internal validity and
observational studies have higher external validity. Thus, they
complement each other and enhance conﬁdence in using the
outcomes to inform decision-making.
Fourth, if an observational study is examining the relative
effectiveness and safety of two different interventions, be suspi-
cious of the robustness of small differences. If the point estimates
of effect by the two treatments do not seem clinically compelling,
then the evidence should be interpreted with caution. Differences
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in the system of health-care delivery can have important effects
on patient outcomes. Ideally, the investigators should deﬁne a
priori what would be considered a clinically meaningful differ-
ence and interpret their ﬁndings in the light of this deﬁnition.
Recommendations
• A standardized approach to reporting of observational
studies should be adopted.
• If there is no RCT to compare to, then should the results run
counter to current understanding of biology and disease
processes, they should not be considered as deﬁnitive but
warranting further investigation.
• The ﬁnding of reproducibility should enhance conﬁdence in
using the outcomes to inform decision-making; neverthe-
less, the absence should not rule out their use in assessing
the body of relevant evidence.
• One can have greater conﬁdence in the ﬁndings of an obser-
vational study, if an analysis of its cohort that is restricted to
a subpopulation that is comparable with that of a published
RCT provides similar results.
• Be suspicious of the robustness of small differences. If the
point estimates of effect by the two treatments do not seem
clinically compelling, then the evidence should be inter-
preted with caution.
How Findings Should Be Interpreted in Light
of Policy Questions
Health policy decisions vary widely in their scope. Increasingly,
governments, payers, and providers are trying to base their deci-
sions on the best available evidence. Nevertheless, numerous
factors affect how ﬁndings are interpreted and whether they are
incorporated into clinical or policy decisions. These include the
direct relationship between the available evidence and the
research question being asked, the magnitude of the observed
effect, the generalizability of the research ﬁndings to broader
populations, the limitations of the study, and the consistency of
the ﬁndings with other available information. There are addi-
tional factors (for example, political and economic factors) that
may alter uptake of research evidence. (We note that health
policy decision-makers must also be informed of potential
conﬂicts-of-interest involved in the generation of information—a
subject beyond the scope of this report.)
Research that appears directly relevant to the policy question
at hand is more likely to be used in decision-making. Although
research is often performed by independent researchers, it is
incumbent upon decision-makers to play a critical role in both
deﬁning the key questions and information characteristics that
will be employed in making policy decisions. This will separately
guide the evidence synthesis and decision-making framework
[32,33]. Once a research question is agreed upon by both poli-
cymakers (the ones who need the information) and researchers
(the ones who design and conduct the retrieval of information),
the design must be rigorous in scientiﬁc principles and feasible in
its implementation. Mock output in the form of ﬁgures and
tables should also be agreed upon by decision-makers and
researchers before research initiation to set expectations on both
sides. Thus, in an ideal world, the process of understanding and
answering the research question in a manner that will be useful
for the decision-maker involves considerable investment of time
by both the researchers and decision-makers at the very early
stages of the research process. This is rarely the case today.
Nevertheless, utilizing this approach would greatly enhance the
impact of comparative effectiveness research on policy.
Researchers should put their ﬁndings into an appropriate
context for policymakers. First and foremost, the ﬁndings of the
study should have a logical relationship to the available relevant
scientiﬁc literature. Findings that contradict the preponderance
of evidence should be viewed with caution. Second, policymakers
should be wary of small differences in effectiveness that may be
statistically signiﬁcant when found through analysis of very large
datasets. Establishing beforehand what degree of clinical differ-
ence would be important from a policy perspective (for example,
a 0.5% absolute reduction in HbA1c level) can help prevent over
interpreting small differences. Third, policymakers should have a
clear understanding of the strengths and limitations of a particu-
lar piece of research as it was conceived, designed, and executed;
following our reporting recommendations will provide this level
of transparency for decision-makers. Special attention should be
paid to the generalizability of the results, the magnitude of con-
founding factors in the analysis, and the extent and degree to
which the analytic plan required adaptation during study execu-
tion. One useful test is to see if one can reproduce ﬁndings of
clinical trials when the population is restricted to subjects who
would have been eligible for the clinical trial. If so, policymakers
can have greater conﬁdence in the direction and magnitude of
differences observed between effectiveness and efﬁcacy.
Our assessment of the strengths and weaknesses of the avail-
able evidence should be based on scientiﬁc principles of research
design—for example, the appropriateness of the study designs,
how well it was executed, the potential sources of bias—and the
magnitude of potential biases, and consistencies of ﬁndings
across multiple studies. At the same time, our willingness to
make decisions based on evidence from nonrandomized studies
will depend on the speciﬁc decisions we are making. In any
decision-making, the risks of acting “too soon” (e.g., acting on
ﬁndings subject to Type 1 error—mistaking a chance effect for a
real one) are always weighed against those of acting “too late”
(e.g., not acting based on ﬁndings subject to Type 2
error—missing a real effect because of studies that are underpow-
ered). Different types of policy decisions may present different
tradeoffs in the tension between the quality of available evidence
and the need to make a decision.
At one end of the spectrum are regulatory decisions such as
drug approval. The criteria for Food and Drug Administration
(FDA) approval—at least two independent randomized trials
with signiﬁcant effects at the 0.05 level and with independent
review of study protocols and data—seek to minimize the
chances of allowing ineffective drugs on the market. These con-
siderations make it unlikely that observational studies would
play a large role in the initial approval process for pharmaceu-
ticals. At the same time, recent studies of diabetes and lipid
lowering drugs have raised concerns about relying on clinical
trials that employ intermediate physiologic end points (e.g.,
glucose or lipid levels) rather than clinical outcomes (e.g., car-
diovascular events) [34,35]. Careful postapproval observational
studies may provide a more practical and politically acceptable
alternative for validating effects on clinical outcomes than the
alternative of requiring hard clinical end points in pivotal trials
for new drugs, which would greatly increase the time and
expense of the approval process.
At the other end of the spectrum, there are situations where
the risks of acting “too late” may look greater than the risk of
acting based on imperfect evidence. Many public health interven-
tions are based primarily on observational evidence, in part
because of the impracticality of requiring evidence based on
randomized studies for interventions such as tobacco restrictions
or seat belt laws. Similarly, because the imitations of RCTs for
assessing drug safety are well known, most signals about safety
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risks are derived from large epidemiologic studies. Responses to
safety concerns can fall on a continuum that includes drug or
device withdrawal; (e.g., IUDs), restrictions on access (e.g., Accu-
tane), prominent “black box” warnings (Celebrex) to clinical
advisories (e.g., Champix/Chantix). These reﬂect both how
strong and consistent the safety signal is, the potential for bias,
the risks posed to the public and the consequences of limiting
access to a potentially beneﬁcial intervention.
Somewhere in the middle lie a range of decisions including
developing recommendations in clinical practice guidelines and
making coverage decisions for public and private insurers. Pro-
fessional societies or other organizations producing evidence-
based guidelines explicitly characterize the strength of individual
recommendations and supporting evidence, and the evidence-
hierarchies traditionally consider evidence from nonrandomized
studies to be weaker than that from randomized trials. The
Grading of Recommendations Assessment, Development and
Evaluation (GRADE) process [36], which has been adopted by a
growing number of international organizations, enumerates a
number of factors that allows one to “upgrade” the quality of
nonrandomized evidence. Equally important, GRADE (as well
as the US Preventitive Services Taskforce) make a distinction
between quality of evidence and strength of recommendation,
noting that one can make strong recommendations even when
evidence is not high quality, for example when potential beneﬁts
far outweigh any potential harms or costs [37]. Of note, many
guideline processes limit search strategies to clinical trials, espe-
cially in areas where trials are more numerous. Although more
efﬁcient, this process runs the risk of missing the potential value
of large databases to answer these additional questions of gen-
eralizability and balance of harms and beneﬁts observed in
typical practice. Clinical recommendations in guidelines have
not yet advanced very far in incorporating understanding of
patient preferences and issues such as adherence and persistence
to treatments. As none of these are well represented in efﬁcacy
trials enrolling highly selected volunteers, data from large obser-
vational databases could be useful for this process.
To have a consistent approach to the use of observational
studies, decision-makers must understand in advance their toler-
ance for error in decision-making. When making comparisons, it
is critical that the comparator chosen be reasonable and relevant
to the decision at hand (What is the best available treatment
alternative? What is the standard of care?) Using certainty and
magnitude of beneﬁt as key dimensions, a multistakeholder EBM
Workgroup has developed a framework for describing judgments
of comparative clinical effectiveness evidence into a matrix as
shown in Figure 1 (with increasing certainty on the vertical axis
and increasing comparative net health beneﬁt on the horizontal
axis [38].
Using such an approach, decision-makers may explicitly take
into account limitations of evidence, including that from obser-
vational studies, with respect to the magnitude of perceived
beneﬁt and the robustness of the ﬁndings. This model is currently
being used in comparative effectiveness reviews by the Institute
for Clinical and Economic Review (ICER, http://www.icer-
review.org).
EBM Matrix
Negative Comparable Small Substantial
Net Benefit    Net Benefit   Net Benefit    Net Benefit
High Certainty
Moderate
Certainty 
Low
Certainty
Comparative Clinical Effectiveness
Comparing tech ___ vs. ____ 
ABCD
II
U/PI I U/P
Figure 1 Framework for describing judgments of comparative clinical effectiveness evidence.
A = “Superior” [High certainty of a substantial comparative net health beneﬁt]
B = “Incremental” [High certainty of a small comparative net health beneﬁt]
C = “Comparable” [High certainty of a comparable comparative net health beneﬁt]
D = “Inferior” [High certainty of a negative comparative net health beneﬁt]
U/P = “Unproven with Potential” [Moderate certainty of a small or substantial comparative net health beneﬁt]
This category is intended to represent bodies of evidence that provide a best estimate in comparative net health beneﬁt as
small or substantial but without enough precision to judge which is more likely.The U/P category also implies that there is
a relatively small possibility that future evidence would demonstrate that the true net comparative beneﬁt is inferior to
other alternatives for many or all patients.
I = “Insufﬁcient” The evidence does not provide high certainty that the net health beneﬁt of the technology is at least comparable with that
provided by the comparator(s).
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Conclusion
Information regarding comparative effectiveness of therapies is
increasing in importance. Nonrandomized studies using second-
ary databases can be designed with rigorous elements and con-
ducted with sophisticated statistical methods to improve causal
inference of treatment effects. The next two sections of our report
will address design and analysis issues directly. When results
from these studies are obtained, we suggest standard methods to
report them, and reasonable caution in interpreting them.
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